LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio and pipeline at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November 2024.

伦敦--（商业新闻短讯）--由葛兰素史克控股的全球艾滋病专家公司ViiV Healthcare，辉瑞和Shionogi为股东，将于2024年11月10日至13日在苏格兰格拉斯哥举行的2024年艾滋病毒格拉斯哥会议上分享其行业领先的艾滋病治疗和预防组合和管道的新数据。

Spanning 42 abstracts, the data showcases long-acting and two-drug regimens as care options for diverse populations in the face of a continuing HIV epidemic..

跨越42篇摘要，数据显示，面对持续的艾滋病毒流行，长效和双药治疗方案可作为不同人群的护理选择。。

Harmony P. Garges, MD, Senior Vice President and Chief Medical Officer at ViiV Healthcare, said: “ViiV Healthcare is the first company to develop and launch long-acting options and two-drug regimens, and these therapies are transforming how physicians and providers treat and prevent HIV today. We continue evaluating how diverse populations living with or impacted by HIV respond to our therapies in the real world.

ViiV Healthcare高级副总裁兼首席医疗官Harmony P.Garges医学博士表示：“ViiV Healthcare是第一家开发和推出长效方案和两种药物方案的公司，这些疗法正在改变医生和提供者今天治疗和预防艾滋病毒的方式。我们继续评估现实世界中感染艾滋病毒或受艾滋病毒影响的不同人群对我们的疗法的反应。

Data from these studies include more than 10,000 people using Vocabria + Rekambys, more than 50,000 people using Dovato and more than 1,300 people using Apretude1. At HIV Glasgow, ViiV Healthcare is showcasing new, compelling data from our portfolio that reinforces how our medicines impact health outcomes and contribute to ending the HIV epidemic.”.

这些研究的数据包括10000多人使用Vocabria+Rekambys，50000多人使用Dovato，1300多人使用Apretude1。在HIV格拉斯哥，ViiV Healthcare展示了我们投资组合中令人信服的新数据，这些数据强化了我们的药物如何影响健康结果，并有助于结束HIV疫情。”。

Key data to be presented at HIV Glasgow 2024 by ViiV Healthcare and its study partners will include:

ViiV Healthcare及其研究合作伙伴将在2024年格拉斯哥艾滋病毒会议上提供的关键数据包括：

Analysis of cabotegravir + rilpivirine long-acting (CAB+RPV LA) in the real-world and across phase 3/3b studies: Findings from a large-scale post hoc analysis of the complete long-acting HIV treatment regimen CAB+RPV LA will be presented. The analysis, which pooled data from over 2,500 participants across four major phase 3/3b clinical trials (FLAIR, ATLAS, ATLAS-2M, and SOLAR), will compare virologic outcomes and isolated viraemic events between daily oral HIV treatment and CAB+RPV LA.2 Furthermore, the real-world utilisation of CAB+RPV LA will be explored in an analysis of adherence and persistence in a Canadian patient support program.

在现实世界和3/3b期研究中对卡博格雷韦+利匹韦林长效（CAB+RPV-LA）的分析：将介绍对完整的长效HIV治疗方案CAB+RPV-LA进行大规模事后分析的结果。该分析汇集了来自四项主要3/3b期临床试验（FLAIR，ATLAS，ATLAS-2M和SOLAR）的2500多名参与者的数据，将比较每日口服HIV治疗和CAB+RPV LA之间的病毒学结果和孤立的病毒血症事件。此外，将在加拿大患者支持计划的依从性和持久性分析中探索CAB+RPV LA的实际应用。

These analyses will add to the growing body of clinical and real-world evidence for CAB+RPV LA and offer additional insights to healthcare providers on outcomes for CAB+RPV LA in diverse populations..

这些分析将增加越来越多的CAB+RPV LA的临床和现实证据，并为医疗保健提供者提供有关不同人群CAB+RPV LA结局的更多见解。。

Data exploring the use of dolutegravir/lamivudine (DTG/3TC) in antiretroviral-naïve people living with HIV: Findings will be presented from the Fundación Huésped-sponsored DOLCE study. This is the first study to fully focus on evaluating the efficacy and safety of the 2-drug regimen DTG/3TC in people living with HIV with CD4 ≤ 200 cells/mm³.3 Additionally, data will be shared from the phase IV D2ARLING study, which compared the efficacy and safety of DTG/3TC against a 3-drug regimen in an antiretroviral-naïve population that did not have baseline drug-resistance testing results available.4 Many guidelines recommend baseline drug resistance testing prior to antiretroviral therapy (ART) initiation, that may not always be readily accessible, reinforcing the need and impact of these data in an antiretroviral-naïve population..

探索在未经抗逆转录病毒治疗的艾滋病毒感染者中使用dolutegravir/拉米夫定（DTG/3TC）的数据：研究结果将来自Fundación Huésped赞助的DOLCE研究。这是第一项全面关注评估双药方案DTG/3TC对CD4≤200细胞/mm³HIV感染者的疗效和安全性的研究。3此外，将分享IV期D2ARLING研究的数据，该研究比较了DTG/3TC与3药方案在未获得基线耐药检测结果的抗逆转录病毒初治人群中的疗效和安全性。4许多指南建议在抗逆转录病毒治疗（ART）开始之前进行基线耐药检测，这可能并不总是容易获得的，这加强了这些数据在抗逆转录病毒初治人群中的需求和影响。。

Cost-effectiveness and usage patterns for long-acting HIV prevention: Findings from a cost-effectiveness study examining the economic and public-health impact of cabotegravir long-acting (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in Canada will be presented. Researchers will compare the impact of the introduction of CAB LA for PrEP against daily oral PrEP (TDF/FTC) and no PrEP usage on cost savings and quality-adjusted life years.5 New findings from the PROTECT survey will be shared, exploring differences in interest and intention to use long-acting PrEP among men who have sex with men and heterosexual men and women in 20 European countries.6,7.

长效艾滋病毒预防的成本效益和使用模式：将介绍一项成本效益研究的结果，该研究检查了卡博格雷韦长效（CAB-LA）对加拿大艾滋病毒暴露前预防（PrEP）的经济和公共卫生影响。研究人员将比较引入CAB LA for PrEP与每日口服PrEP（TDF/FTC）的影响，以及不使用PrEP对节省成本和质量调整生命年的影响。将分享PROTECT调查的新发现，探讨20个欧洲国家男男性行为者和异性恋男性和女性使用长效PrEP的兴趣和意图的差异[6,7]。

Advancing novel mechanisms of action in HIV research: New findings from the BANNER study of VH3810109 (N6LS), an investigational, broadly neutralising antibody (bNAb), will be presented. Previously presented phase IIa proof-of-concept findings from the BANNER study suggested VH109 was well-tolerated and efficacious in people living with HIV.8 Researchers will share new findings exploring the correlation between baseline phenotypic sensitivity to N6LS and virologic response after treatment with N6LS.9 Additional research evaluating N6LS will focus on administration and dose responsiveness, adding to the growing body of evidence supporting the bNAb as a potential new approach to treating HIV.10.

推进艾滋病毒研究中的新作用机制：将介绍VH3810109（N6LS）（一种研究性广泛中和抗体（bNAb））的BANNER研究的新发现。之前提交的BANNER研究的IIa期概念验证结果表明，VH109对HIV感染者具有良好的耐受性和有效性。8研究人员将分享新的发现，探索N6LS基线表型敏感性与N6LS治疗后病毒学反应之间的相关性。9评估N6LS的其他研究将集中在给药和剂量反应性上，增加越来越多的证据支持bNAb作为治疗HIV的潜在新方法。

ViiV Healthcare-sponsored or supported studies to be presented at HIV Glasgow 2024:

ViiV Healthcare赞助或支持的研究将在2024年格拉斯哥HIV大会上发表：

Title

标题

First Author

第一作者

Presentation

演示文稿

Cabotegravir + rilpivirine long-acting

卡替拉韦+利匹韦林长效

Similar virologic outcomes and frequency of isolated viraemic events (blips, low-level viraemia and suspected virologic failure) between oral and long-acting antiretroviral therapy: a pooled analysis of phase 3/3b cabotegravir + rilpivirine long-acting studies

口服和长效抗逆转录病毒疗法之间类似的病毒学结果和孤立的病毒血症事件（斑点，低水平病毒血症和疑似病毒学失败）的频率：3/3b期卡博特格雷韦+利匹韦林长效研究的汇总分析

J. Thornhill

J、 桑希尔

Poster Presentation

海报展示

Real-world utilization of cabotegravir/rilpivirine: an observational analysis of adherence and persistence using a patient support program in Canada, preliminary results

cabotegravir/rilpivirine的实际应用：使用加拿大患者支持计划对依从性和持久性进行的观察性分析，初步结果

C. LaForty

C.LaForty

Poster Presentation

海报展示

Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long-acting (LA) CAB+RPV administration out of HIV units: the IMADART study

在艾滋病毒单位外实施长效（LA）CAB+RPV管理的干预措施（FIM和HIVTISQ）的可行性和满意度：IMADART研究

A. Cabello

A、 头发

Poster Presentation

海报展示

Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine

长效肌内卡博格雷韦联合利匹韦林抗逆转录病毒治疗艾滋病毒感染者的男性和女性生殖液和直肠组织中卡博格雷韦和利匹韦林的浓度以及HIV-1 RNA的抑制

A. Fernández

A、 费尔南德斯

Oral Presentation

口头陈述

Use of long-acting cabotegravir and rilpivirine in a real-life setting: 12-month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH-NA cohort-France

在现实生活中使用长效卡博特格雷韦和利匹韦林：法国ANRS CO3 AquiVIH NA队列中病毒学结果，依从性，安全性，耐久性的12个月结果

M. Hessamfar

M.赫桑帕

Poster Presentation

海报展示

Results at month 7 of CABO-CHANCE study: real-world-evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)

CABO-CHANCE研究第7个月的结果：关于在病毒抑制的HIV感染者（PWH）中每2个月使用一次肌内卡博特拉韦加利比韦林长效（CAB+RPV-LA）的真实世界证据（RWE）

C. H. Tenorio

C、 H.特诺里奥

Poster Presentation

海报展示

Re-suppression regimens and outcomes after virological failure in randomised controlled trials and real-world evidence studies evaluating cabotegravir and rilpivirine (CAB+RPV)

随机对照试验和评估卡博替格雷韦和利匹韦林（CAB+RPV）的真实证据研究中病毒学失败后的再抑制方案和结果

A. Elias

A.埃利亚斯

Poster Presentation

海报展示

Virological failure rate and emergent resistance in real-world studies evaluating long-acting cabotegravir and rilpivirine in people with baseline viral suppression

真实世界研究中的病毒学失败率和紧急耐药性，这些研究评估了基线病毒抑制患者中长效卡博格雷韦和利匹韦林的作用

M. Smuk

M.斯马克

Poster Presentation

海报展示

Cabotegravir long-acting for PrEP

Cabotegravir长效制剂

PrEP-associated stigma in Europe: findings from a real-world survey

欧洲与PrEP相关的污名化：一项现实世界调查的结果

M. Schroeder

M、 施罗德

Poster Presentation

海报展示

Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada

加拿大卡博格雷韦长效注射剂用于HIV暴露前预防的成本效益和公共卫生影响

A. Adelakun

A.阿德拉昆

Poster Presentation

海报展示

Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre-exposure prophylaxis in Europe; the PrEPaRe study

在欧洲使用暴露前预防措施的新诊断艾滋病毒感染者中艾滋病毒耐药性的流行率；PrEPaRe研究

V. Cambiano

五、变更

Poster Presentation

海报展示

Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis

20个欧洲国家正式和非正式PrEP提供途径之间MSM口服PrEP使用模式和使用长效方案意图的差异：潜在类别分析

H. Wang

H、 王

Oral Presentation

口头陈述

Preparing for long-acting PrEP delivery: provider preferences for the provision of long-acting PrEP differ between MSM and heterosexual individuals in Europe

为长效PrEP的提供做准备：欧洲男男性行为者和异性恋者对长效PrEP的提供偏好不同

H. M. L. Zimmerman

H、 M.L.齐默尔曼

Poster Presentation

海报展示

Intention to use long-acting PrEP among heterosexual women and men in 20 European countries – results from the PROTECT survey

PROTECT调查的结果显示，20个欧洲国家的异性恋男女打算使用长效PrEP

K. Jonas

K.乔纳斯

Poster Presentation

海报展示

Dolutegravir

多乐替拉韦

Two-year long-term data on the efficacy and tolerability of dolutegravir-based regimens from the prospective multi-centre TESLA cohort study in ART-naive and pre-treated people living with HIV in Russia

来自前瞻性多中心特斯拉队列研究的基于dolutegravir的方案对俄罗斯未接受抗逆转录病毒治疗和接受过治疗的艾滋病毒感染者的疗效和耐受性的两年长期数据

A. Basova

A.巴索瓦

Poster Presentation

海报展示

The analysis of metabolic parameters in people living with HIV using dolutegravir-based regimens in routine clinical practice in Russia

俄罗斯常规临床实践中使用基于dolutegravir方案的HIV感染者代谢参数分析

A. Basova

A.巴索瓦

Poster Presentation

海报展示

Outcomes following prenatal exposure to DTG-containing antiretroviral therapy regimens: data from the DOLOMITE-EPPICC study

产前暴露于含DTG的抗逆转录病毒治疗方案后的结果：来自DOLOMITE-EPPICC研究的数据

R. Sconza

R.斯坎扎

Poster Presentation

海报展示

Incident hypertension with antiretroviral therapy: real-world evidence from the OPERA cohort

抗逆转录病毒治疗的高血压事件：来自OPERA队列的真实证据

P. Lackey

P、 仆人

Poster Presentation

海报展示

A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE-NEAT ID Network study

一项多中心观察性研究，以确定怀孕期间使用dolutegravir（DTG）的安全性和有效性：来自DOLOMITE-NEAT ID网络研究的数据

J. D. Kowalska

J.D.科瓦尔斯基

Poster Presentation

海报展示

Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia

在欧洲和澳大利亚，使用raltegravir与其他整合酶抑制剂治疗艾滋病毒感染者的死亡率

E. Tusch

R.塔亚尼

Poster Presentation

海报展示

Mental health in PWH: Patient-reported outcomes in the DUALIS study

PWH的心理健康：DUALIS研究中患者报告的结果

E. Wolf

E、 狼

Poster Presentation

海报展示

Evaluating the cardiovascular risk and the achievement of target levels in low-density lipoprotein cholesterol in PLWH: Insights from the DUALIS study

评估PLWH的心血管风险和低密度脂蛋白胆固醇目标水平的实现：来自DUALIS研究的见解

F. Voit

F、看

Poster Presentation

海报展示

Dolutegravir-based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV-negative controls

与HIV阴性对照组相比，基于Dolutegravir的抗逆转录病毒疗法不会降低HIV携带者避孕药使用者的血浆左炔诺孕酮或醋酸甲羟孕酮浓度

R. Ryan

R、 瑞安

Poster Presentation

海报展示

Efficacy and safety of dolutegravir (DTG)-based antiretroviral treatment (ART) in patients with HIV and solid organ transplantation (SOT): A single-arm clinical trial (DTG-SOT)

基于dolutegravir（DTG）的抗逆转录病毒治疗（ART）对HIV和实体器官移植（SOT）患者的疗效和安全性：单臂临床试验（DTG-SOT）

J. Miro

J、 米罗

Poster Presentation

海报展示

Dolutegravir/lamivudine

多替拉韦/拉米夫定

PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States (US)

配对患者报告的使用dolutegravir/拉米夫定（DTG/3TC）治疗的经验和感知益处：对美国（US）从比曲格韦/恩曲他滨/替诺福韦-阿拉芬胺（BIC/FTC/TAF）转换为HIV（PWH）患者的亚分析

J. Slim

J、 苗条的

Poster Presentation

海报展示

Treatment-emergent integrase strand transfer inhibitor (INSTI) resistance-associated mutations among people living with HIV-1 treated with dolutegravir (DTG) + lamivudine (3TC) with pre-existing M184V/I from real-world and interventional studies

来自现实世界和介入研究的预先存在M184V/I的dolutegravir（DTG）+拉米夫定（3TC）治疗的HIV-1感染者中出现的治疗紧急整合酶链转移抑制剂（INSTI）耐药相关突变

D. Fox

D、 狐狸

Poster Presentation

海报展示

An EYEWITNESS to successful diversity in antiretroviral switch studies

见证了抗逆转录病毒转换研究成功的多样性

C. V. Dam

C、 五、大坝

Poster Presentation

海报展示

CARAVEL: evaluation of real-world effectiveness and sustainability of the 2-drug regimen dolutegravir/lamivudine fixed-dose combination in treatment-naive adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France. Two-year interim analysis results

CARAVEL：在法国常规临床护理中，评估2种药物方案dolutegravir/拉米夫定固定剂量组合在未接受治疗的成年人和经病毒学抑制的预处理成年人中的真实有效性和可持续性。两年期中分析结果

P. Philibert

P、 菲利伯特

Poster Presentation

海报展示

Real world experience of DTG+3TC regimen: results from the French Dat'AIDS cohort (2015-2022)

DTG+3TC方案的现实世界经验：来自法国Dat'AIDS队列（2015-2022）的结果

C. Allavena

C、 阿拉维纳

Poster Presentation

海报展示

Changes in patient-reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO-DOBLE randomized clinical trial

病毒学抑制的HIV感染者转换为DTG/3TC或BIC/FTC/TAF的患者报告的神经心理学结果的变化：PASO-DOBLE随机临床试验的子研究

L. Garcia-Fraile

L.Garcia Fraile

Poster Presentation

海报展示

Comparable efficacy and safety of dolutegravir / lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study

dolutegravir/拉米夫定与三药方案在CD4<200/mm3的ARV初治HIV感染者中的疗效和安全性相当：DOLCE研究

M. I. Figueroa

M、 一、菲格罗亚

Oral Presentation

口头陈述

RUMBA’s week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF

伦巴第144周的结果证实了DTG/3TC和B/FTC/TAF的代谢结果令人放心

S. Degroote

S.Degroote

Poster Presentation

海报展示

Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomised D2ARLING study

dolutegravir联合拉米夫定治疗未经基线耐药性检测的HIV感染者的疗效：随机D2ARLING研究的48周结果

E. Cordova

E、 科尔多瓦

Poster Presentation

海报展示

Long-term efficacy and safety of Dolutegravir/Lamivudine in virologically suppressed persons with resistance to Lamivudine: Week 96 results of VOLVER clinical trial - GESIDA 11820

Dolutegravir/拉米夫定对拉米夫定耐药的病毒学抑制患者的长期疗效和安全性：VOLVER临床试验第96周结果-GESIDA 11820

M. De Lagarde

M、 德拉加德

Poster Presentation

海报展示

Fostemsavir

福斯特酸

CD4 T-cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with low-level viremia (LLV) up to Week 192 with fostemsavir (FTR)-based regimens in individuals with multidrug-resistant (MDR) HIV-1

多药耐药（MDR）HIV-1患者的CD4 T细胞，CD4/CD8比率改善以及低水平病毒血症（LLV）至第192周的炎症生物标志物普遍减少

V. Spagnuolo

V.斯帕尼奥洛

Encore Poster Presentation

Encore海报展示

Similar efficacy, safety and CD4 T-cell increase up to Week 96 observed with fostemsavir (FTR)-based regimens in the BRIGHTE study and dolutegravir (DTG)-based regimens in the VIKING-3 study in individuals with multidrug-resistant (MDR) HIV-1

BRIGHTE研究中基于福斯特姆萨韦（FTR）的方案和VIKING-3研究中基于dolutegravir（DTG）的方案在多药耐药（MDR）HIV-1患者中观察到相似的疗效，安全性和CD4 T细胞增加至第96周

A. Castagna

A.栗子

Encore Poster Presentation

Encore海报展示

Pipeline

Correlation of baseline phenotypic sensitivity with virologic response to VH3810109 (N6LS) in BANNER

基线表型敏感性与BANNER对VH3810109（N6LS）的病毒学反应的相关性

M. Gartland

M、 加特兰

Poster Presentation

海报展示

VH3810109 (N6LS) administration dose-responsively enhances anti-HIV antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity in ex vivo models

VH3810109（N6LS）给药剂量反应性地增强了体外模型中抗HIV抗体依赖性细胞毒性（ADCC）和抗体依赖性细胞吞噬作用（ADCP）的活性

M. Keegan

M.基根

Encore Poster Presentation

Encore海报展示

Additional Studies

其他研究

Mortality and clinical outcomes after common cancers in people

人类常见癌症后的死亡率和临床结果

A. Timiryasova

A.蒂米里亚索娃

Poster Presentation

海报展示

The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) Study

在50岁以上人群（罂粟）的药代动力学和临床观察研究中，抗胆碱能药物使用与老年HIV感染者认知功能之间的关系

S. Deb

S.Deb

Poster Presentation

海报展示

Comparison of 4 frailty scores to predict adverse health outcomes and mortality in people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study)

C. Allavena

C、 阿拉维纳

Poster Presentation

海报展示

The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study over a 3-5 year period

在为期3-5年的50岁以上人群（罂粟）药代动力学和临床观察研究中，艾滋病毒感染者中多种药物的患病率和相关因素

L. Sukumaran

L.苏库马兰

Poster Presentation

海报展示

About Dovato

关于Dovato

Dovato is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato..

Dovato被认为是一种完整的治疗方案，用于治疗无抗逆转录病毒（ARV）治疗史的成年人的HIV-1感染，或替代目前的ARV治疗方案，用于病毒学抑制（HIV-1 RNA<50拷贝/mL）的稳定ARV治疗方案，无治疗失败史，对Dovato的任何成分均无已知耐药性。。

Please consult the full Summary of Product Characteristics for all the safety information: Dovato 50 mg/300 mg film-coated tablets.

有关所有安全信息，请参阅产品特性的完整摘要：Dovato 50 mg/300 mg薄膜包衣片。

About Vocabria

关于Vocabria

Vocabria (cabotegravir) injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class..

Vocabria（cabotegravir）注射液与利匹韦林注射液联合使用，用于治疗在稳定的抗逆转录病毒治疗方案中被病毒学抑制（HIV-1 RNA<50拷贝/mL）的成年人中的人类免疫缺陷病毒1型（HIV-1）感染，目前或过去没有病毒耐药性的证据，并且之前没有使用非核苷逆转录酶抑制剂（NNRTI）和整合酶抑制剂（INI）类药物的病毒学失败。。

Vocabria tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:.

Vocabria片剂与利匹韦林片剂联合使用，用于短期治疗在稳定的抗逆转录病毒治疗方案中被病毒学抑制（HIV-1 RNA<50拷贝/mL）的成年人的HIV-1感染，目前或过去没有病毒耐药性的证据，并且之前没有NNRTI和INI类药物的病毒学失败：。

oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long acting rilpivirine injection.

在服用长效奥卡布里亚注射液加长效利匹韦林注射液之前，口服铅以评估奥卡布里亚和利匹韦林的耐受性。

oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection.

口服治疗将错过Vocabria注射液加利匹韦林注射液计划剂量的成年人。

Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant tablets should also be consulted for recommended dosing.

Vocabria片剂仅适用于与利匹韦林片剂联合治疗HIV-1，因此，还应参考Edurant片剂的处方信息以获得推荐剂量。

Please consult the full Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injection and Vocabria 30 mg film-coated tablets

有关所有安全信息，请参阅产品特性的完整摘要：注射用Vocabria 400mg/600 mg缓释混悬液和Vocabria 30 mg薄膜包衣片

About Rekambys

关于Rekambys

Rekambys is indicated - in combination with cabotegravir injection - for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class..

Rekambys与卡博特格雷韦注射液联合用于治疗在稳定的抗逆转录病毒治疗方案中被病毒学抑制（HIV-1 RNA<50拷贝/mL）的成年人的HIV-1感染，目前或过去没有证据表明病毒对NNRTI和INI类药物有抗药性，也没有先前的病毒学失败。。

Rekambys should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing. Rekambys may be initiated with oral lead-in or without (direct to injection).

Rekambys应始终与卡博格雷韦注射液共同给药。建议的剂量应参考卡博特格雷韦注射液的处方信息。Rekambys可以通过口服导入或不使用（直接注射）来启动。

Please consult the full Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection

有关所有安全信息，请参阅产品特性的完整摘要：注射用Rekambys 600mg/900 mg缓释混悬液

About Apretude

关于欣赏

Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir..

Apretude是一种用于预防性传播HIV-1感染（暴露前预防或PrEP）的药物，用于预防体重至少35公斤且感染风险高的成年人和青少年。它应该与更安全的性行为相结合，例如使用避孕套。Apretude含有活性物质cabotegravir。。

Please consult the full Summary of Product Characteristics for all the safety information: Apretude 600 mg prolonged-release suspension for injection

有关所有安全信息，请参阅产品特性的完整摘要：注射用600 mg缓释混悬液

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

商标由ViiV Healthcare group of Companys拥有或授权。

About Fundación Huésped

关于宿主基金会

Fundación Huésped is an Argentine organisation with a regional reach that has been working in public health since 1989, aiming to ensure the right to health and the control of diseases are guaranteed. Our comprehensive approach includes the development of research, practical solutions, and communications related to public health policies in our country and the region.

Huésped基金会（Fundación Huésped）是一个阿根廷组织，自1989年以来一直致力于公共卫生领域，旨在确保健康权和疾病控制得到保障。我们的综合方法包括开发与我国和该地区公共卫生政策相关的研究，实用解决方案和沟通。

Our mission is to conduct scientific research and implement preventive actions and rights-promotion initiatives to ensure access to healthcare and reduce the impact of diseases, with a focus on HIV/AIDS, viral hepatitis, vaccine-preventable diseases, and other transmissible diseases, as well as sexual and reproductive health..

我们的使命是进行科学研究，实施预防行动和权利促进举措，以确保获得医疗保健并减少疾病的影响，重点是艾滋病毒/艾滋病、病毒性肝炎、疫苗可预防疾病和其他传播疾病，以及性健康和生殖健康。。

About ViiV Healthcare

关于ViiV医疗

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012.

ViiV Healthcare是由葛兰素史克（LSE:GSK）和辉瑞（NYSE:PFE）于2009年11月成立的一家全球专业HIV公司，致力于为艾滋病毒感染者和有感染艾滋病毒风险的人提供治疗和护理方面的进步。Shionogi于2012年10月成为ViiV股东。

The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV..

该公司的目标是比以往任何公司都对艾滋病毒和艾滋病产生更深入和更广泛的兴趣，并采取新的方法提供有效和创新的艾滋病毒治疗和预防药物，以及支持受艾滋病毒影响的社区。。

For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.

有关公司、管理层、投资组合、渠道和承诺的更多信息，请访问viivhealthcare.com。

About GSK

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

葛兰素史克是一家全球性的生物制药公司，旨在联合科学、技术和人才共同战胜疾病。更多信息请访问gsk.com。

Cautionary statement regarding forward-looking statements

关于前瞻性声明的警示声明

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024..

葛兰素史克提醒投资者，葛兰素史克所作的任何前瞻性陈述或预测，包括本公告中所作的前瞻性陈述或预测，都存在风险和不确定性，可能导致实际结果与预测结果产生重大差异。这些因素包括但不限于葛兰素史克2023年20-F表年度报告第3.D项“风险因素”中所述的因素，以及葛兰素史克2024年第三季度的业绩。。

Registered in England & Wales:

在英格兰和威尔士注册：

GSK plc

葛兰素史克公司

No. 3888792

编号3888792

ViiV Healthcare Limited

ViiV医疗保健有限公司

No. 06876960

编号：06876960

Registered Office:

注册办事处：

79 New Oxford Street

新牛津街79号

London

伦敦

WC1A 1DG

WC1A 1DG

ViiV Healthcare Limited

ViiV医疗保健有限公司

GSK Medicines Research Centre

葛兰素史克药物研究中心

Gunnels Wood Road, Stevenage

Stevenage Gunnels Wood路

United Kingdom

英国

SG1 2NY

SG1 2NY

References:

参考文献：

1 Data on file

1存档数据

2 J. Thornhill, et al. Similar virologic outcomes and frequency of isolated viraemic events (blips, low-level viraemia and suspected virologic failure) between oral and long-acting antiretroviral therapy: a pooled analysis of phase 3/3b cabotegravir + rilpivirine long-acting studies. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland..

2 J.Thornhill等人。口服和长效抗逆转录病毒治疗之间类似的病毒学结果和孤立病毒血症事件（斑点，低水平病毒血症和疑似病毒学失败）的频率：3/3b期卡博替格雷韦+利匹韦林长效研究的汇总分析。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。。

3 M. I. Figueroa, et al. Comparable efficacy and safety of dolutegravir / lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

3 M.I.Figueroa等人。在CD4<200/mm3的ARV初治HIV感染者中，dolutegravir/拉米夫定与三药方案的疗效和安全性相当：DOLCE研究。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

4 E. Cordova, et al. Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomised D2ARLING study. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

4 E.Cordova等人。dolutegravir联合拉米夫定治疗未经基线耐药性检测的HIV感染者的疗效：随机D2ARLING研究的48周结果。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

5 A. Adelakun, et al. Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

5 A.Adelakun等人。加拿大用于HIV暴露前预防的卡博格雷韦长效注射剂的成本效益和公共卫生影响。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

6 H. Wang, et al. Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

6 H.Wang等人。20个欧洲国家正式和非正式PrEP提供途径之间MSM口服PrEP使用模式和使用长效方案意图的差异：潜在类别分析。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

7 K. Jonas, et al. Intention to use long-acting PrEP among heterosexual women and men in 20 European countries – results from the PROTECT survey. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

7 K.Jonas等人，《在20个欧洲国家的异性恋女性和男性中使用长效PrEP的意图》——PROTECT调查的结果。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

8 P. Leone, et. al. VH3810109 (N6LS) Reduces Viremia Across a Range of Doses in ART-Naive Adults Living with HIV: Proof of Concept Achieved in the Phase IIa BANNER (207959, NCT04871113) Study. Presented at HIV Glasgow 2022, 23 – 26 October, Glasgow, Scotland.

8 P.Leone等人的VH3810109（N6LS）在未接受抗逆转录病毒治疗的艾滋病毒感染者中降低了一系列剂量的病毒血症：在IIa期BANAR（207959，NCT04871113）研究中获得的概念验证。2022年10月23日至26日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

9 M. Gartland, et al. Correlation of baseline phenotypic sensitivity with virologic response to VH3810109 (N6LS) in BANNER. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

9 M.Gartland等人。基线表型敏感性与BANNER对VH3810109（N6LS）的病毒学反应的相关性。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

10 M. Keegan, et al. VH3810109 (N6LS) administration dose-responsively enhances anti-HIV antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity in ex vivo models. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

10 M.Keegan等人，VH3810109（N6LS）给药剂量反应性地增强了离体模型中抗HIV抗体依赖性细胞毒性（ADCC）和抗体依赖性细胞吞噬作用（ADCP）的活性。于2024年11月10日至13日在苏格兰格拉斯哥举行的艾滋病毒格拉斯哥会议上发表。

For media and investors only

仅供媒体和投资者使用